A New Glaucoma Implant Study: Can It Protect Vision, and Can It Bring Lost Vision Back?

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/a-new-glaucoma-implant-study-can-it-protect-vision-and-can-it-bring-lost-vision-back

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

A New Glaucoma Implant Study: Can It Protect Vision, and Can It Bring Lost Vision Back?Glaucoma is a common eye disease that slowly damages the optic nerve (the bundle of nerve fibers that carry visual signals from the eye to the brain), leading to irreversible vision loss (). Most current glaucoma treatments work by lowering the fluid pressure inside the eye. However, even when pressure is controlled, some patients still lose vision over time. Doctors describe this damage as a neurodegenerative process – the nerve cells in the eye’s retina (called retinal ganglion cells) are dying off. Right now, no approved treatments directly protect those nerve cells (). That’s why researchers are excited about a new experimental implant called NT-501 (also known as Encelto). This tiny device continuously releases a nerve-growth protein (ciliary neurotrophic factor, or CNTF) inside the eye, with the goal of neuroprotection – preserving the remaining vision by keeping the retinal nerve cells alive and healthy.What is the NT-501 (Encelto) CNTF implant?The NT-501 implant is a small capsule (about 1×6 mm) that a surgeon places inside the eye (in the gel-like vitreous near the retina) during a minor procedure () (). Inside the capsule are living cells that have been genetically engineered to produce human CNTF, a protein that acts like a “fertilizer” for nerve cells. CNTF belongs to a family of growth factors known to help retinal neurons survive and grow (). Over many months (up to a couple of years), the implant slowly pumps CNTF into the eye. In effect, the implant is like a tiny medicine-pump that continuously bathes the nerve cells in protective growth factor () (). Neurotech Pharmaceuticals (the maker) calls this encapsulated cell therapy Encelto. Notably, the same implant was FDA-approved in 2025 for a different eye disease (macular telangiectasia type 2) (), which shows it can be safely placed in the eye. For glaucoma, doctors hope the constant light dose of CNTF will protect the retinal nerve cells from the stress of glaucoma. What does “neuroprotection” mean?“Neuroprotection” literally means protecting nerve cells. In glaucoma, neuroprotection refers to any treatment that slows or stops the death of the retinal nerve cells, helping to preserve the patient’s existing vision. To explain it simply: if an eye drops from seeing 20/40 to 20/70 every year without treatment, a neuroprotective therapy might slow that decline so the patient stays closer to 20/40 for much longer. In a recent article, Dr. Jeffrey Goldberg (the glaucoma researcher leading these studies) noted that maintaining vision by stopping degeneration is exactly what neuroprotection is meant to do (). (He contrasts this with improving vision beyond the original level – which he called “neuroenhancement” – a higher bar that would mean actually recovering lost vision ().) In short, a neuroprotective treatment protects what you already see, slowing further loss.What did the studies find so far?Early (Phase I) results – small safety trialResearchers first tested this implant in a small safety study. In that Phase I trial, 11 patients with open-angle glaucoma were enrolled (). Each patient had one eye receive the NT-501 implant